Biodistribution and Clearance of Small Molecule Hapten Chelates for Pretargeted Radioimmunotherapy
作者： Kelly Davis Orcutt , Khaled A. Nasr , David G. Whitehead , John V. Frangioni , K. Dane Wittrup
DOI: 10.1007/S11307-010-0353-6
关键词:
摘要: Purpose The favorable pharmacokinetics and clinical safety profile of metal-chelated 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) suggests that it might be an ideal hapten for pretargeted radioimmunotherapy. In effort to minimize retention in normal tissues determine the effect various chemical adducts on vivo properties, a series DOTA-based derivatives were evaluated.
springer.com
sci-hub.se 参考文章(37)
Hazel Breitz, Margaret Tempero, Gregory P. Adams, Susan J. Knox, Louis M. Weiner, Michael L. Goris, David Colcher, Ivan D. Horak, Darrell R. Fisher, Kyle Bryan, Paul L. Weiden, Louis Gentner, Sally Gaffigan, Donald Axworthy, Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clinical Cancer Research. ,vol. 6, pp. 406- 414 ,(2000)
Gary L. Griffiths, Hans J. Hansen, Ken Chang, Habibe Karacay, David M. Goldenberg, Robert M. Sharkey, William J. McBride, A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Research. ,vol. 63, pp. 354- 363 ,(2003)
Warak Chaovapong, Claude F. Meares, Maureen McTigue, Michael J. McCall, David A. Goodwin, Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. The Journal of Nuclear Medicine. ,vol. 29, pp. 226- 234 ,(1988)
Caroline Bodet-Milin, Alain Faivre-Chauvet, Anne Devillers, David M. Goldenberg, Jacques Barbet, Françoise Kraeber-Bodéré, Caroline Rousseau, Ludovic Ferrer, Chien-Hsing Chang, Jean-François Chatal, Loïc Campion, Jean-Philippe Vuillez, Targeting, Toxicity, and Efficacy of 2-Step, Pretargeted Radioimmunotherapy Using a Chimeric Bispecific Antibody and 131I-Labeled Bivalent Hapten in a Phase I Optimization Clinical Trial The Journal of Nuclear Medicine. ,vol. 47, pp. 247- 255 ,(2006)
Anneli Schmitt, Peter Bernhardt, Ola Nilsson, Håkan Ahlman, Lars Kölby, Eva Forssell-Aronsson, Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model. Cancer Biotherapy and Radiopharmaceuticals. ,vol. 20, pp. 231- 236 ,(2005) , 10.1089/CBR.2005.20.231
Philippe Bourrinet, Eric Martel, Abdel I. El Amrani, Pascal Champeroux, Serge Richard, Nicolas Fauchou, Franck Le Coz, Milo Drici, Bruno Bonnemain, Sophie Gaillard, Cardiovascular safety of gadoterate meglumine (Gd-DOTA). Investigative Radiology. ,vol. 42, pp. 63- 77 ,(2007) , 10.1097/01.RLI.0000251565.61487.1A
Kevin J. Hamblett, Brian B. Kegley, Don K. Hamlin, Ming-Kuan Chyan, David E. Hyre, Oliver W. Press, D. Scott Wilbur, Patrick S. Stayton, A streptavidin-biotin binding system that minimizes blocking by endogenous biotin. Bioconjugate Chemistry. ,vol. 13, pp. 588- 598 ,(2002) , 10.1021/BC010087T
Valerie Humblet, Preeti Misra, John V. Frangioni, An HPLC/mass spectrometry platform for the development of multimodality contrast agents and targeted therapeutics: prostate-specific membrane antigen small molecule derivatives. Contrast Media & Molecular Imaging. ,vol. 1, pp. 196- 211 ,(2006) , 10.1002/CMMI.106
Michael G. Stabin, Jeffry A. Siegel, Physical models and dose factors for use in internal dose assessment. Health Physics. ,vol. 85, pp. 294- 310 ,(2003) , 10.1097/00004032-200309000-00006
D. B. Axworthy, J. M. Reno, M. D. Hylarides, R. W. Mallett, L. J. Theodore, L. M. Gustavson, F.-M. Su, L. J. Hobson, P. L. Beaumier, A. R. Fritzberg, Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity Proceedings of the National Academy of Sciences of the United States of America. ,vol. 97, pp. 1802- 1807 ,(2000) , 10.1073/PNAS.97.4.1802